Topic

Vice President – Business Development
LGM Pharma

Articles

Checking in at 2026's midyear mark, LGM Pharma's Mike Stenberg revisits his 2025 predictions on inspections, onshoring, GLP-1 delivery, and AI adoption.

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026

Brian Drapeau is founder, GxPFrame and a cell and gene therapy manufacturing and quality systems consultant.

The future of compliant AI is not better content generation. It is better control over what happens next.

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

Associate Director, IT Applications
Hikma

Manish Garg takes a midyear look back at his 2026 predictions: AI's shift from speed to strategy, supply chain resilience, and why NDC-12 is the next DSCSA moment.

Midyear 2026 Check-In: AI, Supply Chains, and the NDC-12 Story Nobody's Watching

Arcana Life Sciences' Remco Munnik revisits his 2026 predictions on EU regulatory reform, AI adoption, and data governance, and previews pharma's biggest challenges for H2 2026.

Munnik Revisits His 2026 Predictions: A Midyear Check-In on Regulatory Reform, Data, and AI in Pharma

What pharma’s regulatory writers can borrow from clinical AI before the next inspection.

Don’t Make AI Smarter. Make It Traceable.

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

In the concluding segment of a multi-part interview, Jason Bryant of ArisGlobal explains how human-in-the-loop and human-on-the-loop are both still relevant in AI implementation in pharma.

HITL and HOTL: An Air Traffic Control Analogy for Agentic AI

ArisGlobal’s Jason Bryant continues a video supplement to his series of articles on the adoption and implementation of AI agents.

Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the pharmaceutical industry.

Autonomy Isn’t Binary: How Agentic AI Fits into the Pharma Landscape

In this look back at the year that was, in so many ways but in the bio/pharmaceutical industry especially, we remember 2025 as the point in time when AI declared it was here to stay.

The Year of AI: 2025’s Bio/pharma Upskilling Revolution

Machine learning tools are now moving from concept to validated applications, driving transformative shifts in bioanalysis, preclinical testing, and formulation optimization across the industry.

Data and Artificial Intelligence